Background and Purpose-The safety and efficacy of thrombolysis in cervical artery dissection (CAD) are controversial.
A pproximately 2% of all ischemic strokes are caused by cervical artery dissection (CAD). In patients Ͻ50 years of age, CAD accounts for 10% to 25% of all ischemic strokes. 1, 2 CAD is characterized by the presence of an intramural hematoma due to an intimal tear in the carotid or vertebral artery wall. Subsequent ischemic stroke is believed to be caused by thromboembolism in most cases rather than by hemodynamic factors. 3 Randomized controlled trials to investigate thrombolysis in acute ischemic stroke did not exclude patients with CAD. 4 However, safety and efficacy have not been investigated for this particular group in these randomized controlled trials. Therefore, it remains unknown whether thrombolysis can be given in acute ischemic stroke attributable to CAD.
The most serious complication of thrombolysis is symptomatic intracranial hemorrhage (SICH), which occurs in 2% to 9%. 4 In patients with CAD, an additional concern is the risk of enlargement of the intramural hematoma. Small retrospective case series suggested that thrombolysis in CAD patients is safe. 5, 6 The aim of the current meta-analysis was to pool all available case reports and series using individual patient data (IPD) and thus provide a valid estimate of safety and outcome of thrombolysis in patients with CAD-related stroke. In addition, predictors of outcome after thrombolysis in CAD patients were evaluated.
Methods

Study Selection
We systematically searched the PubMed and EMBASE database up to March 2010 for publications on thrombolysis in patients with CAD-related ischemic stroke by using the following combination of variables: ["dissection"] AND ["carotid" or "vertebral" or "cervical" or "extracranial" or "stroke" or "brain ischemia" or "brain infarction"] AND ["thrombolysis" or "recombinant tissue plasminogen activator" or "rtPA" or "tissue plasminogen activator" or "tPA" or "urokinase" or "pro-urokinase"]. In addition, we searched for relevant studies in the Cochrane Library and Cochrane Central Register of Controlled Trials and hand-searched citations from the retrieved studies. Finally, experts in the field were consulted.
We included studies that investigated thrombolysis in patients with CAD-related stroke, either as the main focus of research or as a subgroup analysis. Because the number of publications on this topic is scarce, we did not set a minimum to the number of patients per study. We included publications written in English, German, French, and other languages if an abstract in English, German, or French was available. Patients with a dissection limited to the intracranial part of the vessel(s) only or with an aortic dissection extending into the cervical arteries were excluded. The diagnosis of CAD needed to be confirmed with appropriate imaging tests: color duplex sonography, computed tomography angiography, magnetic resonance angiography, or conventional angiography. Confirmation of the dissection before or after thrombolysis was allowed. Because most studies did not systematically assess the degree of both extracranial and intracranial stenosis before and after treatment, recanalization was not included in our analysis. We analyzed 2 treatment groups: intravenous thrombolysis (IVT) and intra-arterial thrombolysis (IAT). IAT was defined as treatment with IAT only, IVT followed by IAT, or IAT in combination with any endovascular procedure, such as mechanical thrombectomy or stent placement. Thrombolytic therapy had to be administered within 24 hours after stroke symptom onset. The subgroups of patients treated within 3 hours and within 4.5 hours were analyzed separately.
Data Extraction
We collected the following baseline characteristics: sex, age, preceding trauma, stroke severity at presentation as assessed on the National Institutes of Health Stroke Scale (NIHSS), location of the dissected artery (carotid or vertebral), vessel occlusion before treatment, intracranial extension, time from symptom onset to treatment, treatment type (IVT or IAT), and duration of follow-up.
As safety variables, we analyzed SICH, mortality, and recurrent stroke. For the present study, we defined SICH as any intracranial bleeding documented on computed tomography or magnetic resonance imaging that was temporally related to deterioration in the patients' clinical condition. In the included studies, different definitions were used for clinical deterioration. Additional adverse events as reported by the authors were collected and described. We assessed functional outcome by means of the level of dependency at followup. Excellent functional outcome was defined as 0 to 1 on the modified Rankin Scale (mRS), and favorable functional outcome, as an mRS score of 0 to 2. Finally, we performed a subgroup analysis to investigate whether patients with carotid or vertebral artery occlusion had a higher risk of poor functional outcome (mRSϭ3 to 6).
Two independent observers (S.Z., P.N.) extracted all data. Disagreements were resolved by consensus. When the mRS was unavailable, the same observers reconstructed the score if this could clearly be deducted from the case description, according to the mRS criteria. 7 
Individual Patient Data
We sent a uniform datasheet to the authors of all case series with aggregated data only. To prevent double counting of patients who were reported in case series, only the IPD were used for analysis. Authors of case reports were contacted only when the IPD needed for the analysis were incompletely described in the manuscript.
Statistical Analyses
We used the IPD to construct mixed models with the lme4 package of R. 8 We adjusted for the heterogeneity across studies by including a random intercept per study in these models. Pooled proportions were calculated for SICH and mortality, for recurrent stroke and for excellent and favorable outcome. SICH and mortality rates were calculated for the subgroup treated within 3 and within 4.5 hours according to IVT guidelines. These proportions were also calculated for all patients treated with IVT. The following variables were included in univariate models as predictors of excellent and favorable outcome: sex, age, preceding trauma, location of dissected artery, onset-to-treatment time, stroke severity (NIHSS score), and treatment modality. Onset-to-treatment time was analyzed as both a continuous and categorical variable, the latter based on empirically defined cutoff values (Ͻ120 minutes, 120 to 180 minutes, and Ͼ180 minutes). In the multivariate analyses, we adjusted for predictors that were significantly (PϽ0.05) associated with excellent and favorable outcomes in the univariate analyses. A subgroup analysis was performed after excluding data from the case reports.
Comparison With SITS-ISTR
We compared our findings with the results of the Safe Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Register (SITS-ISTR), an ongoing, prospective, international stroke register of patients treated with IVT. 9 Our pooled rates for SICH and functional outcome (including mortality) were indirectly compared with the same end points of selected controls from SITS-ISTR; that is, matched for age and stroke severity (NIHSS score). When a complete match did not exist (allowing a deviation of 1 year or 1 point on the NIHSS score), a control patient was recorded as missing. In SITS-ISTR, SICH was reported according to the definition of both the National Institute of Neurological Diseases and Stroke (any hemorrhage with any neurologic deterioration Ͻ7 days after symptom onset) and the European-Australian Acute Stroke Study II (any hemorrhage with a Ն4-point increase on the NIHSS and likely to be the cause of the clinical deterioration). Functional outcome (mRS) in SITS-ISTR was assessed at 3 months, whereas follow-up duration in our meta-analysis differed among studies. From our IPD, we therefore selected only patients with outcome assessed within 3 months of follow-up.
Results
Studies
Our search strategy yielded 186 citations; 36 publications about 190 patients fulfilled our predefined criteria. All studies were retrospective series or single case reports; no randomized controlled trials were identified. Fourteen case series (160 patients) presented data on thrombolysis in dissectionrelated stroke. 5,6,10 -21 Nine series used data from stroke registries 10, 14, 18, 21 or thrombolysis registries, 5, 11, 16, 22 and 1 was based on a nondefined hospital registry. 15 Of these, 3 studies were multicenter studies. 5, 10, 22 Supplemental Table I (http://stroke.ahajournals.org) gives an overview of the study characteristics of the case series. In addition, 22 case reports were retrieved describing another 24 patients. IPD were available from 33 publications (72 patients). IPD from 108 patients were provided by the authors from the remaining 3 publications that contained aggregated data of 118 patients and from unpublished cases. In total, IPD from 180 patients, all treated with IVT or IAT, were available for the analysis.
Baseline Characteristics
Patients were predominantly female (68%) with a meanϮSD age of 46Ϯ11 years. The median NIHSS score was 16 (interquartile range, 11 to 20), and most patients (60%) presented with severe stroke symptoms (NIHSS score Ն15). Median onset-to-treatment time was 165 minutes (interquartile range, 125 to 225). Treatment was IVT in 67% and IAT in 33%. Six percent of the IVT patients were treated beyond the therapeutic window of 4.5 hours after symptom onset. Baseline characteristics are summarized in Table 1 .
Safety
The pooled mortality was 8.1% (95% CI, 4.9 to 13.2). However, in 7 patients (4%), survival status was unavailable. Pooled mortality in 121 patients treated with IVT was 6.7% (95% CI, 3.4 to 13.8). SICH occurred in 8 of 180 patients (3.1%; 95% CI, 1.3 to 7.2), of which 2 occurrences were fatal. In the IVT group, 4 patients experienced SICH (3.3%; 95% CI, 1.2 to 8.5). Recurrent stroke occurred in 4.5% (95% CI, 2.3 to 8.7) and in 6.8% (95% CI 3.4 to 13.0) of the patients treated with IVT (Tables 2 and 3) .
Other complications after thrombolytic treatment were asymptomatic ICH in 26 patients. One patient with right vertebral artery dissection treated with IVT experienced hematoma expansion (unpublished data), with excellent recovery (mRS scoreϭ1 at 3 months). Pseudoaneurysm at follow-up was reported in 8 of the 133 patients for whom this information was available. One asymptomatic subarachnoid bleeding event occurred. Progression of the infarct defined as worsening of the NIHSS score with intracranial hemorrhage excluded on imaging was reported in 13 of 161 patients.
Functional Outcome
The mRS score was available for 156 patients. In 17 cases, the mRS score could be reliably deduced from the description of functional status. In total, 41.0% (95% CI, 31.4 to 51.4) made an excellent recovery (mRS scoreϭ0 to 1), and 59.5% (95% CI, 52.1 to 66.6) had a favorable outcome (mRS scoreϭ0 to 2). In the IVT group, 33.3% (95% CI, 25.5 to 42.2) had an excellent outcome, and 60.8% (95% CI, 51.8 to 69.1) had a favorable outcome (Tables 2 and 3) .
Median follow-up was 3 months (range, 5 days to 18 months), but 137 patients had their functional outcome Median NIHSS score (IQR) 16 (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) Mild stroke (NIHSS score 1-7), n (%) 21 (15) Moderate stroke (NIHSS score [8] [9] [10] [11] [12] [13] [14] , n (%) 42 (25) Severe stroke (NIHSS score Ն15), n (%) 86 ( 
Regression Models
Predictors of excellent (mRS scoreϭ0 to 1) and favorable (mRS scoreϭ0 to 2) outcome are presented in Supplemental  Table III . In the univariate analyses, only stroke severity (NIHSS score on admission) was inversely associated with both excellent and favorable outcome. The OR for excellent outcome was 0.9 (95% CI, 0.8 to 0.9) for each 1-point increase on the NIHSS. For favorable outcome, this OR was also 0.9 (95% CI, 0.8 to 0.9). Vertebral artery dissection was significantly associated with excellent outcome compared with carotid artery dissection (ORϭ2.6; 95% CI, 1.2 to 5.6) but not with favorable outcome (univariate analysis). Other variables were not associated with outcome. In the multivariate models, we adjusted for stroke severity only. In these models, vertebral artery dissection remained associated with an excellent outcome (ORϭ3.9; 95% CI, 1.4 to 11.1). None of the other variables examined were associated with outcome.
Publication Bias
Leaving out the data from case reports did not alter the main findings. Apparently, there was no publication bias in favor of case reports compared with the results of the larger studies.
Comparison With SITS-ISTR
Selection of controls from SITS-ISTR, matched for age and stroke severity, resulted in 170 eligible cases. Point estimates for the main outcomes of our study compared with SITS-ISTR are shown in Table 4 . Overlapping CIs indicated no relevant differences in SICH rates, mortality, and functional outcome.
Discussion
This meta-analysis of IPD comprises the largest published number of CAD patients treated with thrombolysis to date and suggests that thrombolysis in acute ischemic stroke due to CAD is safe. The pooled SICH rate of 3% and overall mortality of 8% (3% and 7%, respectively, in IVT) in CAD patients are apparently similar to those of stroke from all causes. In particular, the indirect comparison between our population and matched controls from SITS-ISTR did not show relevant differences for these important end points. We did not perform statistical testing of differences between our population and SITS-ISTR, as both studies were not designed beforehand to be compared. We therefore present this comparison only in a descriptive way. However, because placebocontrolled trials on thrombolysis in patients with CAD-related stroke may not be ethical anymore, the presented data may be the best available evidence for clinical guidelines to date.
Expansion of the intramural hematoma during thrombolysis seems to be a rather theoretical concern. In our study, only 1 patient with an intramural hematoma expansion was described but had an excellent outcome. We realize that most studies did not systemically report on this direct complication. However, given the overall safety end points and functional outcome, direct bleeding complications from thrombolysis are apparently not a major issue.
In our population, 31% of all CAD patients had an excellent outcome (mRSϭ0 to 1), compared with 37% in SITS-ISTR. However, a favorable outcome seemed slightly higher in our population (58%, versus 52% in SITS-ISTR). For both outcome measures, the CIs largely overlapped. Therefore, given the fact that we can only make an indirect comparison, the outcome after IVT in patients with stroke due to CAD is in the same range as observed in IVT after stroke from all causes. The subgroup of patients with a priori proven carotid or vertebral artery occlusion may have a higher risk for poor outcome. Because of the small numbers and wide CIs, we could not prove this, and the possible association was not significant. If a higher risk would be found in a larger study in the future, this could imply a different and possibly more aggressive therapeutic approach in this particular subgroup. This still needs to be investigated. Our study has some limitations. First, no randomized trials were available for this meta-analysis. The pooled estimates are based on retrospective and mostly uncontrolled series and case reports only. Although leaving out the case reports did not change our findings, the possibility of publication bias in included series cannot be excluded and might still have influenced the results of this meta-analysis. Another limitation is that we used a pragmatic instead of a strict definition of SICH because the criteria for SICH in the studies contributing to our meta-analysis were heterogeneous. This makes a comparison with SICH rates in other studies difficult. However, our rate with mixed definitions of SICH falls within the rates from SITS-ISTR according to the National Institute of Neurological Diseases and Stroke and European-Australian Acute Stroke Study II definitions. This strongly suggests that the risk of SICH is not increased in patients with CAD-related stroke.
Another point of concern in this study is diagnostic uncertainty in patients with presumed CAD. However, the largest published series included in our analysis excluded patients with "possible" CAD, thereby reducing the diagnostic uncertainty. 5 The type of antithrombotic agents used after thrombolysis was not assessed, which might influence the rate of SICH as well as the outcome. 45 One could argue that we applied a wide treatment window of 24 hours after symptom onset, which is beyond the current guidelines of 4.5 hours for IVT. Median treatment time in our study was 165 minutes (interquartile range, 125 to 225) after symptom onset, indicating that thrombolytic therapy was mostly administered in the very acute phase of the stroke, which was the focus of our study. In the subgroup analysis, we showed that safety and outcome did not differ between patients treated within 3 and within 4.5 hours after symptom onset, in comparison with the entire study population. Finally, the follow-up duration varied among the included studies. Therefore, we present subgroups according to follow-up duration. Moreover, the majority of patients had their follow-up at 3 months exactly, which is similar to that in SITS-ISTR.
Conclusions
In conclusion, thrombolysis appears to be safe in acute ischemic stroke due to CAD. Mortality and SICH rate, as well as outcome, after thrombolysis in these patients appear to be similar to the rates in stroke patients from all causes treated with thrombolysis. Although our analysis is based on retrospective data with small numbers of patients, our results give no evidence that thrombolysis should be withheld in patients with ischemic stroke caused by CAD. 
